Detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery using Bevacizumab-800CW: a single center feasibility and dose finding study - DEPARTURE

niversitair Medisch Centrum Groningen0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- Age >= 18 years
•- Patients with an established diagnosis of PitNET with a Knosp grade of 3 or 4
•who are scheduled to undergo TSS.
•- WHO performance status 0-2
•- Signed written informed consent

•- Medical or psychiatric conditions that compromise the patient's ability to
•give informed consent
•- Pregnant or lactating women. Documentation of a negative pregnancy test must
•be available for woman of childbearing potential. Woman of childbearing
•potential are pre- menopausal women with intact reproductive organs and women
•less than two years after menopause
•- History of infusion reactions to bevacizumab or other monoclonal antibody
•- Inadequately controlled hypertension with or without current antihypertensive
•medications
•- Within 6 months prior to inclusion: myocardial infarction, TIA, CVA,
•pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina

发起方